Reata Pharmaceuticals, Inc.
RETA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $4 | $6 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $3 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -80.7% | 27.4% | -66% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 100% | 100% | -369.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -12,140.1% | -2,119.3% | -2,575.9% | -1,048.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -14,075% | -2,588.2% | -2,747% | -1,094.3% |
| EPS Diluted | -8.59 | -8.19 | -7.35 | -9.54 |
| % Growth | -4.9% | -11.4% | 23% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |